title: [A clinical trial of anti-CD4 CD8 monoclonal antibodies combined with cyclosporine A in treatment of severe aplastic anemia].
abstract: OBJECTIVE
  To explore the safety and efficacy of a therapeutic regimen for treating severe aplastic anemia (SAA) in its early stage.
  
  
  METHODS
  Two groups of SAA patients were enrolled in the present study. One was a treatment group including 21 patients being treated with anti-CD(4), CD(8) monoclonal antibodies as well as cyclosporine A. Another was a control group including 20 patients being treated with anti-lymphocyte globulin and cyclosporine A.
  
  
  RESULTS
  The response rates in the two groups were more or less some, being 76.2% for the treatment group and 65.0% for the control group (P > 0.05), but the blood routine examination results showed quicker recovery in the treatment group than in the control group (P < 0.05) and the incidences of side effects related to therapy such as fever were less in the treatment group than in the control group (P < 0.01).
  
  
  CONCLUSIONS
  The combination of anti-CD(4), CD(8) monoclonal antibodies and cyclosporine A is safe and efficient in treating SAA.
authors.affiliation: Department of Hematology, Taocun Central Hospital of Yantai, Shandong Yantai 265301, China. YXH-yt@163.com
authors.forename: Xu-hua
authors.initials: XH
authors.lastname: Yi
authors.forename: Chun-yan
authors.initials: CY
authors.lastname: Lin
authors.forename: Zhi-hua
authors.initials: ZH
authors.lastname: Hao
authors.forename: Shen-min
authors.initials: SM
authors.lastname: Yan
authors.forename: Chun-yan
authors.initials: CY
authors.lastname: Zhao
authors.forename: Zhao-wei
authors.initials: ZW
authors.lastname: Zhong
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000276:immunology*; D016827:CD8 Antigens / Q000276:immunology*; D002648:Child; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D016827:CD8 Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine